Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Oshikoto Youth Vaccine Hesitant

07/29/2021 | 10:06am EDT

People living in remote areas have shown keen interest in getting vaccinated against Covid-19 as opposed to those living in towns says Oshikoto health director Joshua Nghipangelwa.

"We have recorded a huge number of people in rural areas coming forth for vaccinations, especially at Onandjokwe and Omuthiya districts, while Tsumeb has shown a sluggish figure," he said.

"We don't know why people living in towns are not coming for vaccinations, however, we hope to see an improvement in coming weeks."

In addition, he said, more still needs to be done in Tsumeb to reach a higher number. There are 15 132 doses of Sinopharm in Oshikoto, while the AstraZeneca doses are finished. A total of 7 485 have received their first jab of both Sinopharm and AstraZeneca, while 2 478 are fully vaccinated.

"We are still waiting for more doses to be delivered, but we are told a consignment of AstraZeneca is yet to be delivered. So, I call upon residents to come forth and get their jab, as we have readily available doses of Sinopharm for first and second doses," said Nghipangelwa.

In general, the director says, the vaccination process started very slow, which saw the region lagging in second from bottom on the list of vaccinated people. However, figures started climbing when the directorate reinforced its campaign by boosting fixed points with an outreach programme, complemented by efforts from traditional authorities and regional councillors.

"We have also noted that mostly it is people above 30 years that are coming forth, while those in their 20s are hesitant," he added. "We have a reasonable number of vaccines, therefore, we encourage people, especially those in rural areas, to contact us, when they form a group, and we can administer them. This will help us boost the immune system as well as protect ourselves and the community."

Nghipangelwa said it could be fear of the unknown as well as widespread conspiracy theories that prevent people from getting vaccinated. "Some only tend to understand and want to get vaccinated after they have seen a close relative contracting the virus or someone who died. However, this should not be the case, therefore, I advise the public to voluntarily get the jab so that it can reduce the chances and severity if one gets infected."

Copyright New Era. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about ASTRAZENECA PLC
09/18ASTRAZENECA : IMFINZI plus chemotherapy tripled patient survival at three years ..
09/18ASTRAZENECA : Enhertu reduced the risk of disease progression or death by 72% vs..
09/18ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of dis..
09/18ASTRAZENECA : Enhertu demonstrated robust and durable tumour response of 54.9% i..
09/18ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and..
09/17The case for, and against, COVID-19 vaccine boosters
09/17ASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
09/17ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
09/17AstraZeneca and Daiichi Sankyo Company, Limited Announce ENHERTU® (fam-trastu..
09/17AstraZeneca Sees Positive Results for Enhertu Trial
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,1x
Yield 2021 2,54%
Capitalization 172 B 172 B -
EV / Sales 2021 5,57x
EV / Sales 2022 4,50x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 110,77 $
Average target price 136,08 $
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.09%171 794
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556